Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969419 | 1.00 | SPHK1 (0.50) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL11286875 | 0.98 | SPHK1 (0.52) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL11286877 | 0.98 | SPHK1 (0.52) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL10787221 | 0.96 | SPHK1 (0.47) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL10787226 | 0.96 | SPHK1 (0.47) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL9338782 | 0.89 | CYP2C9 (0.60) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL9442518 | 0.89 | CYP2C9 (0.60) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL10579686 | 0.88 | CYP2C9 (0.54) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL9399116 | 0.88 | CYP2C9 (0.54) | SPHK1CYP2C9ESR2ALDH1A1LMNA | |
| SCHEMBL10381016 | 0.88 | SPHK1 (0.56) | SPHK1CYP2C9ESR2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9234136-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20140138581-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2457888-B1 | Process for isomerization of alkylcyclohexylbenzene | MITSUBISHI GAS CHEMICAL CO (JP) | 2013-12-04 | — | — | EP | disclosed |
| CN-102464590-B | Immunomodulator and preparation method thereof as well as application thereof | SHANGHAI INST MATERIA MEDICA | 2013-10-23 | — | — | CN | disclosed |
| US-20130245067-A1 | DEUTERIUM-ENRICHED LENALIDOMIDE | DEUTERIA PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2017252-B1 | PREPARATION OF 4-(4-ALKYLCYCLOHEXYL)BENZALDEHYDE | MITSUBISHI GAS CHEMICAL CO (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-2457888-A1 | Process for isomerization of alkylcyclohexylbenzene | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-05-30 | — | — | EP | disclosed |
| CN-102464590-A | Immunomodulator and preparation method thereof as well as application thereof | SHANGHAI INST MATERIA MEDICA | 2012-05-23 | — | — | CN | disclosed |
| US-7777081-B2 | 4-(4-alkylcyclohexyl)benzaldehyde | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090118547-A1 | 4-(4-ALKYLCYCLOHEXYL)BENZALDEHYDE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2017252-A1 | 4-(4-ALKYLCYCLOHEXYL)BENZALDEHYDE | Mitsubishi Gas Chemical Company, Inc. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-4572794-A | Acetonitriles, their preparation, and dielectrics and electro-optical display elements containing them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118547-A1 | 4-(4-ALKYLCYCLOHEXYL)BENZALDEHYDE | CYP4F3, AFF4, COXFA4 | SPHK1 2635/4885CYP2C9 86/4885ESR2 2745/4885 |
| US-20130245067-A1 | DEUTERIUM-ENRICHED LENALIDOMIDE | NR3C2, PDCD2L, REN | SPHK1 2116/4885CYP2C9 3260/4885ESR2 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.